Researchers at the University of California San Diego and the Massachusetts Institute of Technology (MIT) have come up with a strategy for using synthetic biology in therapeutics. The approach enables continual production and release of drugs at disease sites in mice while simultaneously limiting the size, over time, of the populations of bacteria engineered to produce the drugs. The findings are published in the July 20 online issue of Nature.
UC San Diego researchers led by Jeff Hasty, a professor of bioengineering and biology, engineered a clinically relevant bacterium to produce cancer drugs and then self-destruct and release the drugs at the site of tumors. The team then transferred the bacterial therapy to their MIT collaborators for testing in an animal model of colorectal metastasis. The design of the therapy represents a culmination of four previous Nature papers from the UC San Diego group that describe the systematic development of engineered genetic clocks and synchronization. Over the years, the researchers have employed a broad approach that spans the scales of synthetic biology,
The new study offers a therapeutic approach that minimizes damage to surrounding cells.
“In synthetic biology, one goal of therapeutics is to target disease sites and minimize damage,” said UC San Diego bioengineering and biology professor Jeff Hasty. He wondered if a genetic “kill” circuit could be engineered to control a population of bacteria in vivo, thus minimizing their growth. “We also wanted to deliver a significant therapeutic payload to the disease site.”
In order to achieve this, he and his team synchronized the bacteria to release bursts of known cancer drugs when a bacterial colony self-destructs within the tumor environment. The use of bacteria to deliver cancer drugs in vivo is enticing because conventional chemotherapy doesn’t always reach the inner regions of a tumor, but bacteria can colonize there. Importantly, the researchers observed that the combination of chemotherapy and the gene products produced by the bacterial circuit consistently reduced tumor size.
“The new work by Jeff Hasty and team is a brilliant demonstration of how theory in synthetic biology can lead to clinically meaningful advances,” said Jim Collins, a professor at MIT who is known as a founder of the field of synthetic biology. “Over a decade ago during the early days of the field, Jeff developed a theoretical framework for synchronizing cellular processes across a community of cells. Now his team has shown experimentally how one can harness such effects to create a novel, clinically viable therapeutic approach.”
Limiting the bacterial population
In order to observe the bacterial population dynamics, the researchers designed custom microfluidic devices for careful testing before investigations in animal disease models. Consistent with the engineering design, they observed cycling of the bacterial population that successfully limits overall growth while simultaneously enabling production and release of encoded cargo. When the bacteria were equipped with a gene that drives production of a therapeutic, the synchronized lysis of the bacterial colony was shown to kill human cancer cells. It is the first engineered gene circuit in synthetic biology to achieve these objectives.
Learn more: Synthetic Biology Used to Limit Bacterial Growth and Coordinate Drug Release
The Latest on: Synthetic biology
[google_news title=”” keyword=”synthetic biology” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Synthetic biology
- Call for Proposals: A Policy Toolkit on Developing International Guidelines on Engineering Biology at Higher Education Levelon May 16, 2024 at 5:00 pm
There are significant barriers to the application of synthetic biology that will have to be overcome before its full potential is realized. Some of these barriers include infrastructure development ...
- Zymergen nears final chapter with Bankruptcy Court settlementon May 16, 2024 at 5:00 pm
Zymergen became primarily an arm's-length synthetic biology service provider to Ginkgo, according to a Bankruptcy Court filing in October. However, according to a declaration from Zymergen's senior ...
- 30 Under 30 Asia: The Founders Developing New Diagnosis Methods And Innovative Healthcare Deviceson May 15, 2024 at 2:12 pm
From diagnosing Parkinson’s to synthetic biology, this year’s Healthcare and Science listees are putting scientific research into practice.
- WPI Researcher Receives $1.2 Million Award to Determine How Environment Impacts Gene Expression in Bacteriaon May 15, 2024 at 12:40 pm
Worcester Polytechnic Institute (WPI) researcher Natalie Farny is launching a $1.2 million, five-year project that could advance the use of bacteria for environmental cleanups by determining how a ...
- Method accelerates the development of sustainable biomaterials from years to minuteson May 15, 2024 at 7:22 am
A study, published in Advanced Materials on May 6, 2024, led by VTT's researchers, introduces a transformative approach that integrates synthetic biology with advanced machine learning and ...
- Fermbox Bio launches its first product in its Synbio product pipeline: A cellulosic enzyme cocktail to transform agricultural waste into 2G ethanolon May 15, 2024 at 3:02 am
Fermbox Bio, a synthetic biology research and manufacturing company, announces the launch of EN3ZYME, a cutting-edge enzyme cocktail designed to enhance both the efficiency and cost-effectiveness of ...
- SBSTTA and SBI—Biodiversity Meetings Crucial for the Global South Beginon May 15, 2024 at 1:23 am
More than 1,400 delegates are present at two crucial meetings, where preserving the planet's biodiversity for the benefit of humanity is under discussion.
- Sojitz Corporation and Ginkgo Bioworks Announce Plans to Use Synthetic Biology R&D Services to Accelerate Sustainable Manufacturing in Japanon May 14, 2024 at 3:08 pm
Sojitz intends to use its extensive network to help Ginkgo foster business connections within the Japanese bioeconomy. TOKYO and BOSTON, /PRNewswire/ -- Sojitz, a lar ...
- Synthetic biology market to rise at a 25.6% CAGR until 2027on May 8, 2024 at 10:45 pm
The global market is expected to grow by $28.25m within the forecast period. The global synthetic biology market is projected to grow by $28.25m at a compound annual growth rate of more than 25.6% ...
- It shouldn’t be easy to buy synthetic DNA fragments to recreate the 1918 flu viruson May 8, 2024 at 1:30 am
The immense potential benefits of biotechnology are profoundly vulnerable to misuse. Better screening of synthetic DNA orders is a key barrier to bad actors.
via Bing News